Adds Amgen comment, lack of response from Harbour, see last two bulleted items

By Blake Brittain and David Thomas

June 12 (Reuters) - Amgen AMGN.O subsidiary Teneobio must pay biotech company Harbour Antibodies $20.2 million in damages for infringing a patent related to antibodies used in biologic drugs, a federal jury in Delaware said on Friday.

The jury agreed with Harbour that Teneobio's UniRat platform violated Harbour's patent rights in technology for using genetically engineered mice to produce antibodies.

• Harbour's Harbour Mice are used to create antibodies for the research, development and production of biologic drugs.

• Biologics are made from biological cells, unlike traditional pharmaceuticals, and are among the most complex and expensive drugs on the market.

• Harbour, a Dutch subsidiary of China-based Harbour BioMed, sued Teneobio in 2021, arguing that Teneobio's UniRat system for genetically engineering rats mimicked its technology.

• Amgen bought Teneobio for $900 million earlier that year to bolster its biologics business.

• Teneobio denied the allegations and argued the patent was invalid.

• An Amgen spokesperson said the company will pursue "certain important legal issues with the court in post-trial proceedings."

• A spokesperson for Harbour did not immediately respond to a request for comment.